title: Regorafenib-Associated Vulvar Psoriasiform Skin Reaction: Case of the Month from the ISSVD Case Consultation Committee.
authors.affiliation: 1Maternity and Gynaecology, John Hunter Hospital, New Lambton Heights, New South Wales, Australia; 2Faculty of Medicine and Health, University of Newcastle, Callaghan, NSW, Australia; and 3Pathology North, Hunter, New England, New Lambton, New South Wales, Australia.
authors.forename: Emma-Lee
authors.initials: EL
authors.lastname: Bourne
authors.forename: Tania
authors.initials: T
authors.lastname: Day
authors.forename: James
authors.initials: J
authors.lastname: Scurry
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D008853:Microscopy; D008875:Middle Aged; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology*; D014845:Vulvar Diseases / Q000139:chemically induced* / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib